Business
Personalis Appoints Christopher Hall as Chief Executive Officer
New Leadership Structure Supports Strategic Objectives to Drive New Paradigm in Cancer Management and Lead in Minimal Residual Disease Testing Aaron
About this update from Personalis, Inc.
[{"type":"text","content":"\nNew Leadership Structure Supports Strategic Objectives to Drive New Paradigm in Cancer Management and Lead in Minimal Residual Disease Testing\n\nAaron Tachibana Promoted to COO and Dr. Richard Chen to EVP, R&D\n\n FREMONT, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as Chief Executive Officer (CEO) and a member of the Board, effective immediately, in addition to his role as President. Hall will lead the Company’s efforts to drive a new paradigm for the active management of cancer with the aim of guiding care from biopsy throughout the life of the patient. Hall joined Personalis in October 2022 and became President at the end of December 2022.\n\nThe Board also promoted Aaron Tachibana to the extended leadership position of Chief Operating Officer (COO), effectively immediately, in addition to his role as Chief Financial Officer (CFO). Tachibana served as Interim CEO since the end of December 2022, and has served as CFO since joining Personalis in 2019, when he led the Company through its initial public offering. In addition, Dr. Richard Chen has been promoted to the position of Executive Vice President, R&D, effective immediately, in addition to his role as Chief Medical Officer (CMO). Dr. Chen, who joined Personalis in 2011 as Chief Scientific Officer, was previously Senior Vice President, R&D and CMO.\n\n“This is a momentous time for Personalis, and we are confident that with this leadership team, we can deliver on our potential to create a new paradigm for the way cancer is actively managed,” said Karin Eastham, Board Chair of Personalis. “The Board thanks Aaron for his role as Interim CEO for the past two months. He, Chris, and Rich led a strategic overhaul to focus on three core areas: winning in the minimal residual disease (MRD) space, enabling customers to develop personalized cancer vaccines, and supporting biopharmaceutical customers with their clinical trials. They have also taken prudent steps to reduce our cash burn, focus on improving margins, and work toward future profitability.”\n\nAdded Eastham, “We are thrilled to welcome Chris, Aaron, and Rich into their new roles, building upon a strong foundation as Personalis evolves into a diagnostic product company and as a c...